Article
Developing DPYD Genotyping Method for Personalized Fluoropyrimidines Therapy.
The journal of applied laboratory medicine - 1 Mar 2024
Wong Betty Y L, Li Zhenyu, Raphael Michael Jonathon, De Angelis Carlo, Hwang David M, Fu Lei
Abstract excerpt
BACKGROUND: Fluoropyrimidine drugs are widely used in chemotherapy to treat solid tumors. However, severe toxicity has been reported in 10% to 40% of patients. The DPYD gene encodes the rate-limiting enzyme dihydropyrimidine dehydrogenase responsible for fluoropyrimidine catabolism. The DPYD variants resulting in decreased or no enzyme activity are associated with increased risk of fluoropyrimidine toxicity. This...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.